Daratumumab Treatment for Chronic Inflammatory Demyelinating Polyradiculoneuropathy ( <scp>CIDP</scp> ): A Case Report
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an immune-mediated neuropathy featuring progressive weakness, sensory deficits, and areflexia. While corticosteroids, intravenous immunoglobulin, and plasmapheresis are effective first-line immunotherapies, a subset of patients remains treatment-refractory. Daratumumab, an anti-CD38 monoclonal antibody approved for multiple myeloma, demonstrates immunomodulatory effects suggesting utility in refractory neuroimmune disorders. However, evidence for its efficacy in CIDP remains limited. We report a case study of treatment-refractory CIDP successfully managed with daratumumab, including 1 year follow-up data.
Authors
- Jing Xu (ORCID: https://orcid.org/0000-0002-6004-4713)
- Jianli Zhao
- Xue Zhao (ORCID: https://orcid.org/0000-0001-8985-1861)
- Y. LI (ORCID: https://orcid.org/0009-0000-6778-7889)
- Xiaowei Hu
- X. Zhang (ORCID: https://orcid.org/0009-0002-4585-6315)
- Jie Wu (ORCID: https://orcid.org/0000-0001-5143-9425)
- Xiaowen Li (ORCID: https://orcid.org/0000-0001-9362-4274)
- Zufei Xiao (ORCID: https://orcid.org/0000-0002-5322-5698)
Institutions
- Tianjin Medical University General Hospital (CN)
- Tianjin Huanhu Hospital (CN)
- Tianjin Medical University (CN)
Publication Details
- Journal
- Annals of Clinical and Translational Neurology
- Published
- 2025-11-27
- DOI
- https://doi.org/10.1002/acn3.70265
- Primary Topic
- Peripheral Neuropathies and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Tianjin City